[A21-121] Tofacitinib (jPsA and pJIA) - Benefit assessment according to §35a Social Code Book V
Last updated 16.02.2022
Project no.:
A21-121
Commission:
Commission awarded on 16.09.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Children's and adolescents' health
Patients with active polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), 2 years of age and older, who have responded inadequately to previous therapy with disease-modifying antirheumatic drugs (DMARDs)
- pJIA, inadequate response to previous therapy with conventional DMARDs (including MTX): added benefit not proven.
- pJIA, inadequate response to previous therapy with one or several biologic DMARDs: added benefit not proven.
- jPsA, inadequate response to previous therapy with one or several DMARDs: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
The current version 1.1 of the Dossier assessment replaces version 1.0 published on 2022-12-15.
| Project no. | Title | Status |
|---|---|---|
| A18-52 | Tofacitinib (Colitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-51 | Tofacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-28 | Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
| A17-18 | Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-115 | Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (new scientific findings) | Commission completed |
| A21-165 | Tofacitinib (ankylosing spondylitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |